Shanghai, China and Summit, NJ, August 1 2023 - BioNova announces 乐舒克® (Belumosudil Mesylate Tablets) has been approved by the China NMPA for the treatment of patients with cGVHD who have an inadequate response to corticosteroids or other systemic treatments.